CTI BioPharma Corp. (DE) Common Stock
CTIC
CTIC was delisted on the 23rd of June, 2023.
145 hedge funds and large institutions have $620M invested in CTI BioPharma Corp. (DE) Common Stock in 2022 Q4 according to their latest regulatory filings, with 37 funds opening new positions, 48 increasing their positions, 37 reducing their positions, and 25 closing their positions.
2,981% more call options, than puts
Call options by funds: $14.5M | Put options by funds: $471K
48% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 25
30% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 37
12% more capital invested
Capital invested by funds: $555M → $620M (+$65.1M)
9% more funds holding
Funds holding: 133 → 145 (+12)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
+$20.6M |
| 2 |
State Street
Boston,
Massachusetts
|
+$12.3M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$9M |
| 4 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$7.67M |
| 5 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$5.43M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$9.51M |
| 2 |
Voloridge Investment Management
Jupiter,
Florida
|
-$9.2M |
| 3 |
PA
Perceptive Advisors
New York
|
-$4.28M |
| 4 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$4.01M |
| 5 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$3.98M |
CTIC Hedge Fund Activity: Q4 2022 in Review
145 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in CTI BioPharma Corp. (DE) Common Stock (CTIC) for Q4 2022, worth a combined $620M — up 12% from $555M a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new CTIC positions and 25 closed out — a net gain of 12 holders — while 48 added to existing stakes and 37 trimmed.
The largest buyer was Bain Capital Life Sciences Investors, opening a new position worth an estimated $20.6M. The largest seller was Driehaus Capital Management, exiting entirely with an estimated $9.51M sold.
- 145 institutional investors held CTI BioPharma Corp. (DE) Common Stock (CTIC) as of Q4 2022, up from 133 in Q3 2022.
- Funds reported $620M of CTI BioPharma Corp. (DE) Common Stock stock for Q4 2022, up 12% quarter-over-quarter.
- 37 funds opened new CTI BioPharma Corp. (DE) Common Stock positions in Q4 2022 and 25 closed out, a net change of +12 holders.
- The largest CTI BioPharma Corp. (DE) Common Stock buyer in Q4 2022 was Bain Capital Life Sciences Investors, an estimated $20.6M added.
- The largest CTI BioPharma Corp. (DE) Common Stock seller in Q4 2022 was Driehaus Capital Management, an estimated $9.51M sold.
Based on aggregated 13F filings for Q4 2022.